Literature DB >> 27895798

Exploring the impact of EGFR T790M neighboring SNPs on ARMS-based T790M mutation assay.

Sanpeng Xu1, Yaqi Duan1, Liping Lou1, Fengjuan Tang1, Juan Shou1, Guoping Wang1.   

Abstract

The present study aimed to explore the influence of T790M neighboring single nucleotide polymorphism (SNP) on the sensitivity of amplification refractory mutation system (ARMS)-based T790M mutation assay. Three ARMS-quantitative polymerase chain reaction (qPCR) systems (system 1 had a forward ARMS primer without rs1050171, system 2 included a forward ARMS primer with rs1050171 and system 3 contained the above two forward ARMS primers) were used to detect the T790M mutation in two series plasmid samples and genomic DNA (gDNA) of the cell line H1975. A total of 670 formalin-fixed paraffin-embedded (FFPE) tumor samples from non-small cell lung cancer patients were used to detect the epidermal growth factor receptor (EGFR) gene T790M mutation by direct sequencing and ARMS-qPCR. The ARMS-qPCR system 1 effectively detected samples with as low as 1% T790M mutant plasmid 1 (without rs1050171) and with 50% T790M mutant plasmid 2 (with rs1050171), while the ARMS-qPCR system 2 detected samples with 20 and 50% T790M mutant plasmid 1, in addition to samples with 1% T790M mutant plasmid 2. For the ARMS-qPCR system 3, samples with as low as 1% T790M mutant plasmids 1 or 2 were effectively detected. For gDNA analysis of the cell line H1975, the T790M mutation was effectively detected by the ARMS-qPCR systems 2 and 3 (~50% mutation rate), but was detected with a low mutation abundance by the ARMS-qPCR system 1 (~1% mutation rate). Of the 670 FFPE samples, 5 cases were identified to have the T790M mutation by sequencing and by the ARMS-qPCR system 1. One sample (named N067), which was considered as T790M-negative by sequencing, was demonstrated to have the T790M mutation using the ARMS-qPCR system 1. Sample N094, which was variant homozygous for rs1050171 and was indicated to be T790M-negative by sequencing and by the ARMS-qPCR system 1, was identified to have the T790M mutation with the ARMS-qPCR system 3. The A-variant allele frequency of rs1050171 was observed to be 28.2% in the 670 FFPE tumor samples, while the presence of rs148188503 (c. C2355T, p. T785T) was observed in sample N558, and a novel SNP with a base substitution (c. T2375C) at position 792 (p. L792P) in exon 20 of the EGFR gene was observed in sample N310. rs1050171 is a high-frequency SNP located near T790M, and the mutation statuses of rs1050171 appear to influence the sensitivity of the ARMS-based T790M detection system, thus generating a 14.3% false-negative rate (1/7). The present study proposes the risk that target neighboring SNPs (as far as 8 bp away in the present study) may exert on the sensitivity of ARMS-based detection methods.

Entities:  

Keywords:  amplification refractory mutation system; epidermal growth factor receptor gene T790M mutation; non-small cell lung cancer; rs1050171; single nucleotide polymorphism

Year:  2016        PMID: 27895798      PMCID: PMC5104263          DOI: 10.3892/ol.2016.5184

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  28 in total

1.  Molecular haplotype determination using allele-specific PCR and pyrosequencing technology.

Authors:  Monica Pettersson; Mattias Bylund; Anders Alderborn
Journal:  Genomics       Date:  2003-09       Impact factor: 5.736

Review 2.  EGFR T790M resistance mutation in non small-cell lung carcinoma.

Authors:  Marc G Denis; Audrey Vallée; Sandrine Théoleyre
Journal:  Clin Chim Acta       Date:  2015-02-07       Impact factor: 3.786

3.  Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing.

Authors:  Roman K Thomas; Elizabeth Nickerson; Jan F Simons; Pasi A Jänne; Torstein Tengs; Yuki Yuza; Levi A Garraway; Thomas LaFramboise; Jeffrey C Lee; Kinjal Shah; Keith O'Neill; Hidefumi Sasaki; Neal Lindeman; Kwok-Kin Wong; Ana M Borras; Edward J Gutmann; Konstantin H Dragnev; Ralph DeBiasi; Tzu-Hsiu Chen; Karen A Glatt; Heidi Greulich; Brian Desany; Christine K Lubeski; William Brockman; Pablo Alvarez; Stephen K Hutchison; J H Leamon; Michael T Ronan; Gregory S Turenchalk; Michael Egholm; William R Sellers; Jonathan M Rothberg; Matthew Meyerson
Journal:  Nat Med       Date:  2006-06-25       Impact factor: 53.440

4.  Wobble-enhanced ARMS method for detection of KRAS and BRAF mutations.

Authors:  Julian Hamfjord; Astrid M Stangeland; Martina L Skrede; Kjell M Tveit; Tone Ikdahl; Elin H Kure
Journal:  Diagn Mol Pathol       Date:  2011-09

5.  Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Authors:  Masahiro Fukuoka; Yi-Long Wu; Sumitra Thongprasert; Patrapim Sunpaweravong; Swan-Swan Leong; Virote Sriuranpong; Tsu-Yi Chao; Kazuhiko Nakagawa; Da-Tong Chu; Nagahiro Saijo; Emma L Duffield; Yuri Rukazenkov; Georgina Speake; Haiyi Jiang; Alison A Armour; Ka-Fai To; James Chih-Hsin Yang; Tony S K Mok
Journal:  J Clin Oncol       Date:  2011-06-13       Impact factor: 44.544

6.  Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays.

Authors:  Jun Wang; Ramesh Ramakrishnan; Zhe Tang; Weiwen Fan; Amy Kluge; Afshin Dowlati; Robert C Jones; Patrick C Ma
Journal:  Clin Chem       Date:  2010-03-05       Impact factor: 8.327

7.  An efficient procedure for genotyping single nucleotide polymorphisms.

Authors:  S Ye; S Dhillon; X Ke; A R Collins; I N Day
Journal:  Nucleic Acids Res       Date:  2001-09-01       Impact factor: 16.971

8.  The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.

Authors:  Youngwook Kim; Jeonghun Ko; ZhengYun Cui; Amir Abolhoda; Jin Seok Ahn; Sai-Hong Ou; Myung-Ju Ahn; Keunchil Park
Journal:  Mol Cancer Ther       Date:  2012-01-06       Impact factor: 6.261

9.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Authors:  Wenjun Zhou; Dalia Ercan; Liang Chen; Cai-Hong Yun; Danan Li; Marzia Capelletti; Alexis B Cortot; Lucian Chirieac; Roxana E Iacob; Robert Padera; John R Engen; Kwok-Kin Wong; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal:  Nature       Date:  2009-12-24       Impact factor: 49.962

10.  Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.

Authors:  R E Board; G Ellison; M C M Orr; K R Kemsley; G McWalter; L Y Blockley; S P Dearden; C Morris; M Ranson; M V Cantarini; C Dive; A Hughes
Journal:  Br J Cancer       Date:  2009-10-27       Impact factor: 7.640

View more
  6 in total

1.  Evaluation of PCR-HRM, RFLP, and direct sequencing as simple and cost-effective methods to detect common EGFR mutations in plasma cell-free DNA of non-small cell lung cancer patients.

Authors:  Jamal Zaini; Elisna Syahruddin; Muhammad Yunus; Sita Laksmi Andarini; Achmad Hudoyo; Najmiatul Masykura; Refniwita Yasril; Asep Ridwanuloh; Heriawaty Hidajat; Fariz Nurwidya; Sony Suharsono; Ahmad R H Utomo
Journal:  Cancer Rep (Hoboken)       Date:  2019-02-03

2.  Two missense variants of the epidermal growth factor receptor gene are associated with non small cell lung carcinoma in the subjects from Iraq.

Authors:  Zahraa K Lawi; Mohammed Baqur S Al-Shuhaib; Ibtissem Ben Amara; Ahmed H Alkhammas
Journal:  Mol Biol Rep       Date:  2022-09-28       Impact factor: 2.742

3.  Lung cancer mutation testing: a clinical retesting study of agreement between a real-time PCR and a mass spectrometry test.

Authors:  Phillip Shepherd; Karen L Sheath; Sandar Tin Tin; Prashannata Khwaounjoo; Phyu S Aye; Angie Li; George R Laking; Nicola J Kingston; Christopher A Lewis; J Mark Elwood; Donald R Love; Mark J McKeage
Journal:  Oncotarget       Date:  2017-09-16

4.  Detection of somatic mutations in ctDNA derived from adenocarcinoma patients - EGFR tyrosine kinase inhibitor monitoring preliminary study.

Authors:  Marzena Anna Lewandowska; Ewelina Nalejska; Łukasz Żołna; Aleksandra Chrząstek; Bogdan Żurawski; Magdalena Wiśniewska; Manuela Las-Jankowska; Krzysztof Roszkowski; Janusz Kowalewski
Journal:  Contemp Oncol (Pozn)       Date:  2019-06-13

5.  The EGFR Polymorphism Increased the Risk of Hepatocellular Carcinoma Through the miR-3196-Dependent Approach in Chinese Han Population.

Authors:  Li Zhang; Xiaoping Li; Jiang Lu; Yi Qian; Tao Qian; Xing Wu; Qinghua Xu
Journal:  Pharmgenomics Pers Med       Date:  2021-04-23

6.  A comparison of MASS-PCR and ARMS-PCR for the detection of lung cancer gene mutation.

Authors:  Ling Cai; Weidong Wang; Fang Wang; Rusi Zhang; Lanjun Zhang; Huiwei Qi; Weiquan Gu; Ningning Zhou
Journal:  Transl Cancer Res       Date:  2019-11       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.